The clinical information you need, at your fingertips.

A single infusion of VERVE-102, designed to mimic the lifelong protection seen in people born with loss-of-function PCSK9 variants, delivered durably lower LDL-C. . .

Propensity-matched analysis suggests GLP-1 receptor agonists may reduce progression to stage IV disease across multiple solid tumors. . .

Tirzepatide produced greater reductions in HbA1c, body weight, and waist circumference than standard care at two years, with most patients reaching near-normal blood sugar. . .

Updated ACR recommendations emphasize rapid disease control, less steroid reliance, and targeted DMARD strategies. . .

Datopotamab deruxtecan-dlnk is the first TROP2-directed antibody-drug conjugate for patients who aren't candidates for PD-1/PD-L1 inhibitor therapy. . .

A small biomarker analysis identified a perivascular immune signature in pre-treatment tumor tissue that may help identify patients more likely to benefit from nivolumab plus ipilimumab. . .

A new position paper makes 11 recommendations aimed at protecting clinical autonomy and patient care, pointing to evidence that PE acquisitions are tied to higher costs, increased adverse events, and workforce instability without consistent quality improvement. . .

Savings were largest in oncology, urology, psychiatry, and cardiology, where high-cost generics are common and median absolute savings exceeded $100 per prescription. . .

Ancestry-linked lipid metabolism differences track with treatment response in mCRPC. . .